Background. No specific data have been published on primary renal disease (PRD) in young adults with end-stage renal failure (ESRF). For children, congenital abnormalities of the kidney and urinary tract (CAKUT) account for 50% of renal failure and other congenital and familial disease comprise 20%. This remains true for teenage children in paediatric registries. Results. For the UK, there is a rise in the rate of 'aetiology uncertain' from 6% at 12-15 years to 21% by 18-21 years. This figure of 21% remains constant for the older patients in their third and fourth decades and can be increased by at least 5% by adding 'glomerulonephritis; histologically examined but unspecified'; but these figures compare with unknown rates of 36% for the US age group 20-29 years. In the UK, for those 18-21 years, 'glomerulonephritis' accounts for 28%, when 'Alport's disease' (6.5%) and 'unspecified' (4.5%) are excluded, which compares with age 12-15 of 26%. At age 18-21 years in the UK, there is a sharp decline in all CAKUT (26%) when compared with the BAPN incidence for the 12-15 age group of 45%. For those in their third decade, diabetes accounts for 14-18% of diagnoses, distorting our ability to compare data by percentage. Conclusions. These young adult data in the UK are consistent with the hypothesis that many of the undiagnosed cases must be CAKUT or tubular disease.
Introduction
There is very little data published on primary renal disease (PRD) in young adults. This study analyses PRD in young adults with end-stage renal failure (ESRF) reported to the UK Renal Registry and the US Renal Data System (USRDS registry).
Many patients have no given diagnosis ('aetiology uncertain'). The UK Renal Registry reports a rate of 21% for 'aetiology uncertain' in the age group 20-65 years [1] . Why is it so high? Is it lower in young adults in whom a diagnosis may be easier? A trend found throughout the paediatric registries has been a reduction in the number of children with no given diagnosis. The British Association of Paediatric Nephrology (BAPN) publishes an annual report of the incidence and prevalence of renal failure in children (aged 0-15) [2, 3] and, in their latest analysis, the rate of 'uncertain aetiology' is only 3.0% [4] . This compares with 39% in 1976 [5] .
Review of the current paediatric literature shows that, worldwide, around half of all renal failure in children is caused by some form of congenital abnormality of the kidney and urinary tract (CAKUT) and a further 20% from other congenital and familial disease (CONGEN) [6] . The BAPN, up to and including their 2006 report, recorded 'dysplasia' and 'reflux nephropathy' separately, but they have since taken the view that 'Renal dysplasia, with or without vesico-ureteric reflux (VUR), is the most common cause of ESRF in the childhood population. On the basis that the clinical overlap between reflux nephropathy and renal dysplasia is so great and that clinical distinction between these two groups is quite arbitrary, these two categories have been united' [4] . The BAPN data on diagnosis are very detailed and serve as a gold standard for comparative studies. This is a review of the UK Renal Registry data for England and Wales for the period 2000-2006. The adult registry data are incomplete before the age of 18 and so I have reviewed in detail PRD in the age range 18-39 years. For comparison, USRDS data are available for analysis in decades starting with 0-19 years and then 20-29 and 30-39 years. One reason for this analysis was the expectation that renal dysplasia/reflux (non-obstructive CAKUT) is underdiagnosed in adult clinics and tubular disease almost never diagnosed.
Materials and methods
Data recorded in registries as 'missing' are excluded and the denominator for analyses is the sum of all remaining patients listed with a given diagnostic code. Thus, if data on 1000 patients were provided but the PRD was missing (not provided) in 50 cases, the denominator for analysis of that set of data would be 950.
ESRF and end-stage renal disease (ESRD) are synonymous terms for the date when renal replacement therapy began.
To estimate incident rates per million population (pmp) per year, we have used mid-2007 population estimates for males and females in the UK aged 16-29 and applied them to the population aged 18-31. This total population is 11,334,300 [7] .
BAPN data
The data quoted are taken from an analysis of the UK Renal Registry report for the year 2006 published in NDT [3] . This was based on 913 patients, aged below 16 years, who had reached ESRF in the period 1996-2005.
The BAPN data are summarized in 14 diagnostic groups (see Table 1 ). The European Dialysis and Transplant Association (EDTA) codes corresponding to each BAPN diagnostic group are shown in column 1 of Table 2 . Renal dysplasia and reflux nephropathy are combined as renal dysplasia ± VUR [4] (Diagnosis Group 1). For comparison, the UK Renal Registry and USRDS data are also summarized using the same categories. 'Glomerular diseases' include Alport's syndrome (EDTA Code 51).
UK renal registry
The UK Renal Registry provided an Excel file of (i) age at ESRF and (ii) PRD for all patients aged 18 and over and registered with them in the period 2000-2006. There were 33,615 patients, of whom 4182 ('young adults') were aged 18-39 years at the onset of ESRF. PRD was recorded as 'unreported' (missing) in 249 young adults (6.0%), leaving 3933 patients for analysis.
UK Registry data from the paediatric units and reported by BAPN are for ages 0-15 years. For the UK data, there is an age group of 16-17 years for whom the data are incomplete (and not included in this analysis).
The EDTA codes for PRD are shown in Table 2 . Individual diagnoses for patients with glomerulonephritis are also summarized in Table 3 .
'Congenital renal dysplasia with or without urinary tract malformation' (EDTA Code 63) was not often used; but in this analysis, I have assumed that there was a urological problem (obstructive uropathy).
Unknown diagnosis: Most registries have one or more categories for 'aetiology uncertain'/'no specific diagnosis'. In addition, some diagnoses are not authenticated. Thus, the following categories have all been classed as 'ESRF of uncertain aetiology':
(1) Chronic renal failure; aetiology uncertain (EDTA Code 0), (2) Glomerulonephritis; histologically NOT examined (EDTA Code 10).
To conform to the BAPN analysis, we have included 'glomerulonephritis; histologically examined, not given above (EDTA Code 19)' as a part of Diagnostic Group 2 (glomerulonephritis), while recognizing that many of these will be 'unknown diagnosis'.
Similarly, many classified as 'other identified renal disorders (but not specified) (EDTA Code 99)' are likely to be 'unknown diagnosis', but in Table 1 , they are shown as diagnosis 14 'other unspecified diagnoses'.
Within the BAPN report (2007) [3] , there is also PRD data analysis on four age sub-groups of 0-3, 4-7, 8-11 and 12-15 years. To compare as closely as possible with these data, we have analysed a UK sub-group aged 18-22 years.
USRDS data are available in decades 20-29 and 30-39 years (see below). For comparison with this data, we have also analysed UK age groups of 22-31 and 32-40 years.
USRDS data
The USRDS provided 'incident counts of reported ESRD patients by demographic characteristics & detailed primary diagnosis' for each year from 1991 to 2005. The data for 2005 were analysed for the age groups 0-19 (n= 1112), 20-29 (n=2521) and 30-39 (n=5575). (The data reported here have been supplied by the USRDS. The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the US government.)
The US data are reported in such a way that, for any individual diagnosis, patient number of <10 is not available.
Unknown diagnosis: For this analysis, the following categories have all been classed as 'ESRF of uncertain aetiology': The USRDS codes do not have a category of 'glomerulonephritis; histologically examined but unspecified' (equivalent to EDTA Code 19).
Summary and comparison data
We have also summarized the data in three groups as follows:
(1) CAKUT: are renal dysplasia ± VUR with and without obstructive uropathy. The EDTA codes used for this and other groups are highlighted in Table 2 .
(2) CONGEN: are the tubular, cystic, other hereditary nephropathies and metabolic diseases shown in Table 2 . Alport's syndrome and all pa- Table 4 .
For comparison: Published data from the following paediatric registries are presented in Table 4: (1) North American Pediatric Renal Transplant Cooperative Study (NAPRTCS), since 1994, has enrolled children younger than 21 years at their first reported clinic visit that have an estimated glomerular filtration rate (GFR) <75ml/min/1.73m 2 as calculated by the Schwartz formula. In 1998, they reported demographic data in age groups on 1725 patients seen in the period 1994-96 [8] (see Table 4 ). Data have also been analysed from their 2006 report in which PRD is reported separately for renal insufficiency, dialysis and transplant patients [9] . 
Results

BAPN data
Published data on PRD from the 2006 registry report on 913 children are summarized in 14 diagnostic groups (Table 1) [3] . 
Data for 0-15years and order and style of individual diagnoses derived from ref. [3] . With the following modifications: (i) primary focal segmental glomerulosclerosis-EDTA focal segmental sclerosis (Codes 11 and 17) combined into one group; (ii) HUS-diarrhoea positive and negative HUS combined into one group; (iii) proliferative GN has no equivalent in EDTA codes; (iv) paediatric 'vasculitis (unspecified)' assumed equivalent to EDTA 'multi-system disease-other (not mentioned above)' (Code 89); (v) EDTA has no microscopic polyarteritis nodosa; (vi) others = systemic sclerosis (two cases), cryoglobulinaemia (one case). BAPN data obtained from ref. [3] ; NAPRTCS data from ref. [6] ; ANZDATA from ref. [8] . CAKUT, congenital abnormalities of the kidney and urinary tract; CONGEN, other congenital and familial diseases (includes Alport's); uncertain, aetiology uncertain (EDTA Code 0) and glomerulonephritis; histologically NOT examined (EDTA Code 10), plus 'glomerulonephritis; histologically examined, not given above (EDTA Code-19)'; glomerulonephritis, all primary and secondary glomerulonephritis except Alport's syndrome (EDTA Code 51) and 'glomerulonephritis; histologically examined, not given above' (EDTA Code 19); miscellaneous, other diagnoses (specified or unspecified) but not in given PRD categories.
It can be seen that renal dysplasia (32%) and obstructive uropathy (15%) are, respectively, the first and third most common diagnoses and, together as CAKUT, they represent 47% of all diagnoses. In Table 4 , the data are shown for the age sub-groups, and the proportions of CAKUT and CONGEN are similar from ages 4 to 15.
Glomerulonephritis is the second commonest group of which 'primary focal and segmental glomerulosclerosis (FSGS)' accounts for almost half (42%) of the group and 9.5% of all patients (Table 3) .
UK adult data
For every EDTA-coded primary renal diagnosis, the percentage reported for each age group (18-21, 22-31 and 32-39 years) is shown in Table 2 . By age 22-31 years, diabetes accounts for 14% of diagnoses, distorting our ability to compare data by percentage.
The most conspicuous change in diagnosis between ages 12-15 and 18-21 years is the rise in 'ESRF of uncertain aetiology' from 6% [4] to 21.4% (Table 4) . To this latter figure can probably be added another 4.5% (glomerulonephritis; histologically examined, diagnosis not given above [19] ) and 2.0% (other identified renal disorders EDTA Code 99). Thereafter, this amount of undiagnosed PRD remains constant (Table 1) .
Apart from this rise in unknown diagnosis, there is a fall in renal dysplasia and an apparent rise in glomerulonephritis (see Table 1 ). The individual diagnoses in the glomerulonephritis group are summarized for the different age groups (Table 3) .
For those 18-21 years, in all 'glomerulonephritis' (39%) is the most common diagnosis, but when Alport's syndrome (6.5%) and 'unspecified' (4.5%) are excluded, they account for 28% of all PRD, which compares with 26% for the age group 12-15 years. IgA nephropathy accounts for 6.3% of all patients compared with 1% for the BAPN data.
By age 22-31 years, the glomerulonephritis group (100%) is principally IgA nephropathy (32%), FSGS (10%) and 'unspecified' (15%), with IgA accounting for 10.2% of all cases of renal failure in this age group (see Table 3 ).
Incident rates of different diagnoses pmp per year have been estimated for all in the age group 18-31. There were 1950 patients (24.6 pmp) of whom 1844 (23.2 pmp) had their PRD reported. Uncertain aetiology was 5.1 pmp to which 1.1 pmp 'glomerulonephritis unspecified' can be added (total 6.2 pmp-see Table 1 for details). Total primary glomerulonephritis was 4.0 pmp, which included IgA nephropathy 2.2 pmp. IgA for 18-31 years is 55% of all known primary glomerulonephritis (43% of all primary glomerulonephritis including unspecified) and 9.4% of all ESRF.
USRDS
The unknown rate in the 0-19 age group is high (21%), in contrast to UK paediatric data of 3.2% [2, 3] . This rises to 36% in the next two decade age bands (see Table 1 ).
In both age groups 0-19 and 20-29 years, glomerulonephritis accounts for 32% of all diagnoses. When the paediatric group (0-19, n=356 cases) is compared with the sum of UK data from 0-15 plus 18-21 years (n = 359 cases), the sums are the same and there are few differences except for the diagnosis of SLE (82 vs 16 cases in UK), with SLE accounting for 23% of all USRDS glomerulonephritis diagnoses (individual data are not shown). FSGS accounted for 46% of the group, and haemolytic-uraemic syndrome (HUS), Henoch-Schoenlein and IgA nephropathy each 8%. When the third decade groups are compared, the commonest diagnosis is SLE (34%) closely followed by FSGS (30%). IgA accounts for 15%, which is less than half the rate in UK (32%).
Discussion
The striking finding is the high incidence of 'unknown' diagnosis (aetiology uncertain) which in the UK rises from 6% at 12-15 years to 21% by 18-21 years. This figure of 21% for the unknown group remains constant for older patients in their third and fourth decades. It can probably be increased by 4.5% by adding 'glomerulonephritis; histologically examined but unspecified' [19] ; but these figures compare with unknown rates of 36% for the USRDS age group 20-29 years.
Why do so many young patients have no known diagnosis? Undoubtedly, there is a problem with poor or incomplete reporting to large national registries. For example, for the 0-19 age group reported to USRDS, the unknown rate is 21%, while, in contrast, the paediatric registry for USA and Canada (NAPRTCS) have only a 2% rate [9] . An example of poor reporting can be seen in the in the Annual UK Renal Registry report. Of 58 centres reporting 2006 data on 'percentage distribution of primary renal diagnosis', 13 had incidence rates for 'uncertain aetiology' >30% (range 31-98%, median 47%). The total for all 58 centres combined was 26% [1] .
One likely explanation for a genuine failure to make a diagnosis is that many of these patients probably present at or close to ESRF, when a diagnosis is difficult and a biopsy would not be easy and often inconclusive. Paediatricians reporting to their registries do not now, however, seem to share this diagnostic problem.
Could a significant number of these undiagnosed cases be patients with unrecognized renal dysplasia/reflux (CA-KUT)? The UK data show that, at age 18-21 years, CA-KUT accounts for only 26% when compared with the BAPN data that report an incidence for the 12-15 age group of 45%. NAPRTCS enrols 'children' up to 21 years of age and their annual report gives separate data on PRD for children with renal insufficiency, on dialysis and those with transplant. In the 2006 NAPRTCS report, the incidence of CAKUT was 52% for chronic renal insufficiency compared with 39% for all ESRF [9] . For the 13-20 age group with chronic renal insufficiency, the incidence of CAKUT was reported as 47% [8] . The Italian (ItalKid) project has not reported age sub-group data, but for all its patients up to 20 years of age (mean age at presentation 7 years), CAKUT accounts for 61% (43% for those who reached ESRF) [11] . These figures from the USA and Europe would not lead one to expect that, in UK, there is an incidence of only 26% for CAKUT at age 18-21. I believe that these published data support the view that CAKUT is under-diagnosed in this post-adolescent group in the UK.
How complete is the UK data? In England in 2007, acceptance rates were 28 pmp for 20-24 years, 36 pmp for 25-29 years, 39 pmp for 30-34 years and 69 pmp for 35-39 years [1] . In this data, for age 18-31, there were 24.6 pmp. This slightly lower than expected figure presumably reflects the units that did not report data.
Although end-stage patients with proteinuria are often considered to have primary glomerulonephritis, we have previously argued that, with the possible exception of hereditary glomerular disease, primary glomerulonephritis does not present at end stage without previous symptoms [6] . Tubular disease, in contrast, can. It typically progresses slowly and asymptomatically with minimal proteinuria, without salt and water retention and often normal blood pressure. Similarly, with renal dysplasia/reflux nephropathy, although declining renal function in renal disease is associated with increasing amounts of proteinuria, symptoms may be minimal and blood pressure may be normal until end stage is reached [12] [13] [14] . Thus, we would argue that patients presenting at end stage with no previous history are not often likely to have glomerulonephritis, but are likely to have renal dysplasia/reflux (CA-KUT) or tubular disease. If these patients were biopsied, they would likely to be diagnosed as either (secondary) FSGS or tubulo-interstitial disease (TID).
There is reluctance to biopsy patients with advanced renal failure but can we learn more from such patients that have been biopsied and reported in large national biopsy registries (see Table 5 )? In particular, concerning the incidence of IgA nephropathy and TID. In the Italian registry, 21% of patients had chronic renal insufficiency (creatinine >1.5mg/dl) of whom 17% had IgA nephropathy and 6.6% had FSGS [16] . In Spain, 12% were biopsied principally because of renal insufficiency (creatinine >1.5mg/dl) of whom 19% had IgA and 14% had FSGS [19, 24] . In the Czech series, 48% had renal insufficiency (23% had a creatinine 111-200µmol/L, 14% 200-400µmol/L, 12% >400 µmol/L) [21] . In the first group, IgA accounted for 21% and, in the third group, IgA was 7.7%. The Czech data also suggest that, as IgA nephropathy decreases with advancing renal insufficiency, TID increases; so that they found 5.5% TID in the first group and 12% in the third. In Italy, they also found an increase in TID with worse function so that overall TID was annually 4% (range 2.8-4.7), while for those with renal insufficiency, it rose to 6% [16] . The Australian study reported incident rates for which IgA nephropathy was 43 pmp and TID 14 pmp [18] . In the study from China, 4.5% of patients had a creatinine above 300µmol/L whose biopsies showed IgA 27%, FSGS 10%, TID 12% and unknown 11% [22] . This increases the consensus that around 10% of patients biopsied with advanced renal insufficiency are likely to have TID. The incidence of TID in our 18-31 age group was 0.5 pmp (or 2%).
It is often assumed that new patients presenting with ESRF together with some proteinuria and a little haematuria must have end-stage primary glomerulonephritis. What is the evidence that many from the unknown group could have primary glomerulonephritis? The commonest form of primary glomerulonephritis is IgA nephropathy and it is also the commonest glomerular cause of ESRF [25] . In the absence of a family history and overt symptoms, is it possible Table 5 ). The few published data, however, on incident rates are from small populations that will result in wide variation around the true situation. In our UK data for the age group 18-31 years, 43% of all primary glomerulonephritis was IgA nephropathy. This is similar to data from large biopsy registries in which figures for IgA nephropathy range from 37% to 48% (see Table 5 ), although these studies will include conditions such as minimal change disease which do not result in ESRF. In our data, IgA nephropathy accounted for 9.4% of all ESRF and this was equivalent to an incident rate of 2.2 pmp. The few data that are available from biopsy registries report incident rates for IgA of 8.4-15.6 pmp ( Table 5 ). If we assume that over a 10-year period 20% might at most reach ESRF, then 20% of 15.6 is 3.1 pmp; but this outcome is only true for those with a GFR below 60ml/min or proteinuria at least 2+ [26] , which is uncommon in children with IgA nephropathy. This compares with our estimated figure of 2.2 pmp for IgA and 4.0 for all primary glomerulonephritis. The peak incidence of IgA diagnosis is around 25-35 years of age so one would expect a peak of ESRF from IgA nephropathy a decade or two later (Table 5) . IgA nephropathy is relatively rare in children, although it is still the most common diagnosis (19%) found at biopsy [16] . In Australia, where IgA nephropathy is very common, the biopsy incident rate for males aged 5-14 years was 14 pmp. Thus, it is most unlikely that the highest reported incident rates of ESRF of 6.0-8.0 pmp (which were reported from small populations) would apply to the age group 18-31 years and it seems very unlikely that IgA nephropathy is under-diagnosed in the age group 18-31. Even if we increased our figure by 50% (1.1 pmp), IgA and other primary glomerulonephritis could not account for more than a fraction of the total unknown group of 6.2 pmp.
One major weakness of this type of review is the difficulty in comparing data from age to age and country to country when it is expressed as a percentage. This becomes apparent by the third decade when the incidence of diabetes starts to distort the other figures. Registry data need to be expressed as incidence and prevalence in terms of population. Finnish data concerning PRD, for example, are already expressed as incidence per million population. This was possibly prompted by the comparatively large groups of young Finns with amyloid, type 1 diabetes and congenital nephrosis which makes the comparison of data from other countries by percentage meaningless [27] .
Conclusion
In conclusion, full data must be collected and reported as incident rates (pmp per year). Once we know the incidence of patients that cannot be currently categorized, then studies can be planned to determine the true identity of their renal disease. It is likely that many in the age group 18-31 will have renal dysplasia and some tubular disease.
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Appendix: comments on coding systems UK data: The EDTA codes were drawn up over 40 years ago and have essentially not been revised. This leads to some confusion and ambiguity with categorizing PRD.
Particular issues are 'FSGS with nephrotic syndrome in children' [11] and 'FSGS with nephrotic syndrome in adults' [17] , which are the same condition; but there is no category for the more common ;'secondary FSGS'-with its many causes, most notably reflux nephropathy.
In the summary of the BAPN data [4] , the CAKUT group is divided into (i) renal dysplasia ± VUR and (ii) obstructive uropathy. Currently, Prune belly syndrome and megacystis megaureter are in the renal dysplasia group [3] , but it might be more appropriate to have all patients with abnormal bladder function in the same 'obstructive uropathy' group. Although Alport's disease is a type of glomerulonephritis, it might be more appropriate to have it listed with other congenital forms of glomerulonephritis (in the sense that it is not an acquired, immunological disease that might be treated with immunosuppressive drugs).
USRDS data: The interpretation of the USRDS codes is straightforward, with the exception of a catch all 'focal glomerulosclerosis, focal sclerosing' [5] , which has to cover the entire range of FSGS-related pathology, except for HIV-associated nephropathy (AIDS nephropathy; USRDS Code 65′).
Supplementary data
Supplementary data is available online at http://ndt.oxfordjournals.org. 
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